IGC Pharma, Inc.

What they do

IGC Pharma operates as a single reportable segment focused on Alzheimer's disease after consolidating its former Life Sciences and Infrastructure segments in fiscal 2025. Its lead asset, IGC-AD1, is in the Phase 2 CALMA trial for agitation in Alzheimer's dementia, with preclinical candidates TGR-63, LMP, IGC-M3, IGC-1C and IGC-1A behind it and AI-based work on early Alzheimer's markers. The company also cites use of an internal contract research organization to advance its pipeline.

Revenue drivers

• Single reportable segment (Alzheimer's-focused life sciences) — Management determined the company operates as one reportable segment in fiscal 2025; the former Infrastructure segment produced revenue in fiscal 2024 but none in fiscal 2025 and is no longer separately managed.
• Product revenue — Annual revenue was $1.3M in fiscal 2025, flat with fiscal 2024; the filings provide no product-level or customer-level revenue split.

Recent performance

Fiscal 2025 revenue was $1.3M, unchanged from $1.3M in fiscal 2024, while net loss narrowed to $7.1M from $13.0M. Diluted EPS improved to -$0.09 in fiscal 2025 from -$0.22 in fiscal 2024, and operating cash flow was -$4.8M versus -$5.2M. In the latest quarter ended June 30, 2026, revenue was $265 thousand, down from $328 thousand in the quarter ended June 30, 2025. At June 30, 2026, total assets were $9.5M, total liabilities $3.4M, shareholder equity $6.1M and cash and equivalents $331 thousand.

Strategy

IGC's stated focus is advancing IGC-AD1 through the ongoing Phase 2 CALMA trial and ultimately to commercialization, while investing in preclinical candidates and AI-powered models for early Alzheimer's markers. The company expects to keep incurring substantial expenses for clinical development of IGC-AD1 and other candidates. It has reassessed its reporting around a single Alzheimer's-focused segment and is disposing of non-core assets. It also cites leveraging an internal contract research organization for execution efficiency and building a longer-term portfolio spanning symptomatic and disease-modifying therapies.

Risks

• Dependence on IGC-AD1 — The company states its business is highly dependent on the successful development and regulatory approval of IGC-AD1, which remains subject to Phase 2 risks including patient follow-up, evaluability, database lock and safety findings.
• History of losses and accumulated deficit — Net losses were $7.1M in fiscal 2025 and $13.0M in fiscal 2024, and the company expects continued substantial expenses, which may limit its ability to raise capital.
• Low cash and working capital — Cash and cash equivalents were approximately $405 thousand and working capital approximately $639 thousand as of March 31, 2025, and cash was $331 thousand at June 30, 2026.
• Financing and dilution via recent agreements — Since the last 10-K the company reported several events involving material agreements, direct financial obligations and unregistered sales of equity, including on 2026-07-06 and 2026-04-20.

Outlook

Management's stated near-term priority is executing and completing the Phase 2 CALMA trial for IGC-AD1 and reporting topline results, though it notes the trial remains subject to follow-up, data cleaning, database lock and analysis risks. Preclinical milestones cited in the 10-K include bioequivalence of LMP to IGC-AD1 anticipated in 2025 and toxicology studies for IGC-M3 planned for mid-2025. The company expects to continue incurring substantial development expenses without a stated timeline for profitability.